.Pharmacolibrary.Drugs.R_RespiratorySystem.R01B_NasalDecongestantsForSystemicUse.R01BA01_Phenylpropanolamine.Phenylpropanolamine .Pharmacolibrary.Drugs.R_RespiratorySystem.R01B_NasalDecongestantsForSystemicUse.R01BA01_Phenylpropanolamine.Phenylpropanolamine| name: | Phenylpropanolamine |
| ATC code: | R01BA01 | route: | oral |
| n-compartments | 1 |
Phenylpropanolamine is a sympathomimetic agent formerly used as a decongestant and appetite suppressant. It acts primarily as a norepinephrine releasing agent. Due to concerns over hemorrhagic stroke risk, it is no longer approved for use in many countries including the United States.
Pharmacokinetic parameters reported for healthy adult volunteers (sex not always specified) following single oral administration.
Olsson, B, & Landgren, BM (2001). The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Clinical therapeutics 23(11) 1876–1888. DOI:10.1016/s0149-2918(00)89083-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11768839
Jiang, F, et al., & Shin, JG (2013). Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals. Pharmacogenetics and genomics 23(3) 175–179. DOI:10.1097/FPC.0b013e32835de25e PUBMED:https://pubmed.ncbi.nlm.nih.gov/23292115
Siami, P, et al., & Lama, D (2002). A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clinical therapeutics 24(4) 616–628. DOI:10.1016/s0149-2918(02)85137-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12017406